Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 11Not yet recruiting 4Terminated 3Unknown 2Completed 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Carcinoma, Non-Small-Cell Lung 22Breast Neoplasms 8Stomach Neoplasms 7Lung Neoplasms 7Small Cell Lung Carcinoma 5Rectal Neoplasms 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Esophageal Squamous Cell Carcinoma 4Recurrence 3NSCLC 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Muscle-invasive Bladder Cancer 2Multiple Myeloma 2Mesothelioma, Malignant 2Limited Stage Small Cell Lung Cancer 2Leukemia, Myeloid, Acute 2Esophageal Neoplasms 2Urologic Neoplasms 1Upper Tract Urothelial Carcinoma 1Thymus Neoplasms 1Sleep Initiation and Maintenance Disorders 1Resectable Non-small Cell Lung Cancer 1Pathologic Complete Response 1

Interventions

Carboplatin 12pembrolizumab 8Paclitaxel 8Cyclophosphamide 8toripalimab 4sacituzumab govitecan 4olaparib 4Epirubicin 4Drug Therapy 4Doxorubicin 4eribulin 3Capecitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2Radiotherapy 2Injections 2Gemcitabine 2taxane 1poly ICLC 1pirfenidone 1palbociclib 1ivarmacitinib 1inavolisib 1fludarabine 1daratumumab 1camrelizumab 1axatilimab 1anlotinib 1aldesleukin 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Triple Negative Breast Neoplasms × Drug Therapy × Clear all
NCT07556848 2026-04-30

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 3 Not yet recruiting
356 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Harbin Medical University

Phase 1/2 Not yet recruiting
12 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07101614 2025-08-03

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

Shengjing Hospital

Phase 2 Not yet recruiting
125 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06691594 2025-02-20

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡